Paper

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Published Dec 1, 2018 · A. Tron, M. Belmonte, Ammar Adam

Nature Communications

377

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Highly Cited

Study Snapshot

AZD5991, a Mcl-1-specific inhibitor, shows potential in inducing rapid apoptosis in cancer cells, with potential for treatment of multiple myeloma and acute myeloid leukemia.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

References

Citations